Topic: nonalcoholic steatohepatitis (NASH)
Boehringer is swallowing Enleofen’s anti-IL-11 antibody platform, putting it on the hook for up to $1 billion in milestones per product.
The financing comes months after NorthSea enrolled the first NASH patient in the trial of its structurally engineered fatty acid icosabutate.
Durect’s stock nose-dived more than 30% yesterday on the news that its phase 2 plaque psoriasis hope failed to beat out a sham treatment.
Our final roundup of biotech news for the year and the decade.
As we reach the end of the year, we look back on the most read stories of the last 12 months.
NASH has been among the closely watched indications in biotech since January 2014.
As we come to the end of 2019 and the twenty-teen era, we look ahead to what we see as the biggest and most pressing issues facing biotech in 2020.
We may be nearing the first-ever approval for a NASH drug next year, but the road to approval is not getting easier.
Gilead's NASH prospects firsocotat and cilofexor failed to move the needle on liver scarring in a phase 2 study, on their own or in combination.
NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.